PURPOSE: Use of beta blockers as a predictor of mortality has not been well investigated in patients with cardiac resynchronization therapy (CRT). The purpose of this study is to evaluate the impact of beta blockers in predicting mortality in CRT patients.
METHODS: We studied 100 consecutive patients who received CRT (male 73, female 27, age 69.9± 9.6 years). Optimal pharmaceutical regimen established prior to bi-ventricular pacemaker implantation. The record of beta blockers use was noted after CRT.
RESULTS: There were 91 patients who received beta blockers. Eighteen patients died from the heart failure during follow-up of 17± 10.6 months. The beta blockers and another 9 variables were related to cardiac mortality by univariate regression (p< 0.1). After adjustment for the 10 variables that achieved a significant level, the use of beta blockers was still related to mortality [odds ratio (OR) = 0.08, 95%CI 0.01- 0.54, p= 0.009] by multivariate regression. The use of beta blockers was associated with a near 13-fold decrease in mortality in patients with CRT. Left atrial volume index (OR= 1.62, p= 0.01) and Creatinine Clearance (OR= 10.1, p= 0.005) were also related to mortality.
CONCLUSION: Patients who had received beta blockers were associated with 13-fold decrease in mortality in patients with CRT.
CLINICAL IMPLICATIONS: Beta blockers is recommended in patients with cardiac resynchronization therapy.
DISCLOSURE: Chandra Nair, No Financial Disclosure Information; No Product/Research Disclosure Information